Glucosylceramidase beta 1 (GBA1)

Glucosylceramidase beta 1 (GBA1) is a lysosomal enzyme encoded by the GBA1 gene, responsible for catalyzing the hydrolysis of glucocerebroside into glucose and ceramide within lysosomes[3][7][9]. Deficiency of this enzyme, most often due to inherited mutations, leads to abnormal accumulation of glucocerebroside and related metabolites, causing Gaucher disease, a lysosomal storage disorder presenting with multisystem involvement[3][1][5]. Heterozygous and some non-pathogenic GBA1 mutations are the most common known genetic risk factor for Parkinson disease and related synucleinopathies[1][2][4]. GBA1 and its product, glucocerebrosidase (GCase), play central roles in lysosomal integrity, neuronal maintenance, and glycolipid catabolism[6][8]. Therapeutic targeting includes enzyme replacement, substrate reduction, pharmacological chaperones, and emerging gene therapies; neurological manifestations remain difficult to treat due to limited CNS penetration of current therapies[1][6][8]. The GBA1 gene product is a singular and essential enzyme for both rare (Gaucher) and common (Parkinson) diseases, and is under active investigation for disease modification.

Other names

GlucocerebrosidaseGCaseGBAGLUCGLCM_HUMANacid β-glucosidaseD-glucosyl-N-acylsphingosine glucohydrolase

Enzyme replacement restores or supplements defective glucocerebrosidase activity; Substrate reduction lowers buildup of glucocerebroside by inhibiting its synthesis; Pharmacological chaperones stabilize mutant enzyme, enhancing its lysosomal delivery and activity; Experimental gene therapy aims to restore functional enzyme through gene transfer